Alpha Peptides PT-141 (bremelanotide) is sold as a research peptide, not an FDA-approved drug. Learn forms, dosing ranges, duration, and safety.
Alpha Peptides PT-141 is the bremelanotide peptide sold by the vendor Alpha Peptides as a laboratory research chemical. Bremelanotide itself is FDA-approved as Vyleesi, an injectable prescription drug for premenopausal women with hypoactive sexual desire disorder (HSDD), but research-grade vials are not approved, tested, or labeled for human use. That distinction matters for anyone comparing pt 141 peptides from different suppliers.
What Is PT-141 and How Does It Work?
PT-141 is a synthetic cyclic heptapeptide and a melanocortin receptor agonist. It is an analog of alpha-melanocyte-stimulating hormone, and it appears to act mainly in the central nervous system rather than on blood vessels.
Researchers studying the compound focus on three things:
- Receptor target: It binds melanocortin receptors, with the strongest activity at MC4R, which is involved in appetite, mood, and sexual desire pathways.
- Mechanism: It seems to influence desire signals in the brain instead of improving blood flow the way PDE5 inhibitors like sildenafil do.
- Routes studied: Subcutaneous injection is the FDA-approved route, and intranasal delivery has also been tested.
PT-141 is not approved to treat erectile dysfunction in men. The only FDA-approved use covers premenopausal women with HSDD.
Alpha Peptides PT-141 vs. Prescription Bremelanotide
Both products contain the same active molecule, but the regulatory and quality picture is very different. The table below summarizes the main differences.
| Feature | Alpha Peptides PT-141 (research grade) | Vyleesi (FDA-approved) |
|---|---|---|
| Regulatory status | Sold as a research chemical; not FDA-approved | Approved by the FDA in 2019 |
| Intended use | Laboratory research only | HSDD in premenopausal women |
| Typical form | Lyophilized powder, sometimes a nasal spray | Single-use auto-injector pen |
| Labeled dose | No human dose on the label | 1.75 mg subcutaneous, as needed |
| Quality checks | Varies by vendor; the COA may not be third-party | GMP manufacturing with lot release testing |
| Legal access | No prescription; personal use is a legal gray area | Prescription required |
Purity documentation is the most useful thing to check. A certificate of analysis with HPLC purity data and a mass-spec identity match tells you more than any marketing claim on a product page.
PT-141 Forms: Injection vs. Nasal Spray
Bremelanotide has been delivered in more than one way, and each route behaves differently in the body.
- Subcutaneous injection: The approved format, delivered with a single-use auto-injector into the abdomen or thigh.
- pt-141 nasal spray: An older intranasal version was studied for erectile dysfunction in men, and absorption through the nose is less predictable than an injection.
- Lyophilized powder: The form most research vendors ship; it requires reconstitution with bacteriostatic water and careful cold storage.
Dose for dose, an intranasal product usually delivers a smaller share of the peptide to the bloodstream, which is one reason results from different routes are not interchangeable.
Reported Dosing Ranges
Dosing information for PT-141 comes from published clinical trials and the FDA label. The only FDA-labeled pt-141 dosage for women is a single 1.75 mg subcutaneous injection, given at least 45 minutes before anticipated sexual activity and limited to one dose in 24 hours and no more than eight doses per month.
| Population | Route | Reported dose | Notes |
|---|---|---|---|
| Premenopausal women (label) | Subcutaneous | 1.75 mg | Maximum 1 dose per 24 hours and 8 doses per month |
| Women in trial arms | Subcutaneous | 1.25 mg to 1.75 mg | Nausea and flushing were the most common side effects |
| Men in research settings | Intranasal or subcutaneous | Varies widely across studies | Not an approved indication; results have been mixed |
Forum posts often discuss dosing for men and women with far more confidence than the published data supports. Anyone evaluating a protocol should read the primary literature rather than a summary thread.
How Long Does PT-141 Last?
A common question is how long does pt-141 last after a single dose. After a subcutaneous injection, blood levels typically peak within about an hour, and the elimination half-life is roughly 2.7 hours.
In practical terms, users and trial participants generally report a window of several hours, often described as six to twelve hours, with effects fading gradually. That timeline is why the label restricts dosing to once every 24 hours.
Several factors can change the timeline:
- Route of administration, such as injection versus nasal spray
- Body weight and individual metabolism
- Whether the person has eaten recently
- Other medications being taken at the same time
Where to Buy PT-141 and How to Vet a Vendor
Knowing where to buy pt-141 is only part of the job, because judging whether a supplier is credible takes more work. Alpha Peptides, Paradigm Peptides, and dozens of smaller shops list the compound, and the listings often look nearly identical.
- Third-party COA: Look for purity above 98% from an independent lab rather than a self-reported number.
- Identity testing: A mass spectrometry report should match the expected molecular weight.
- Labeling: A responsible research vendor prints "not for human consumption" on the vial.
- Shipping and storage: Lyophilized peptide should arrive with clear handling and storage instructions.
Research-grade PT-141 is sold with a disclaimer that it is not for human use. Buying it for personal use sits in a legal gray area, and the FDA has sent warning letters to vendors that market peptides with drug-like claims.
Safety and Legal Considerations
Bremelanotide is not a benign compound. The FDA label lists nausea, flushing, headache, and injection-site reactions as the most common side effects, and it warns about transient increases in blood pressure and heart rate.
People with uncontrolled high blood pressure or cardiovascular disease should not use bremelanotide. Focal hyperpigmentation of the face and gums has also been reported, particularly with repeated use.
Two points are worth repeating:
- PT-141 is not FDA-approved for men or for erectile dysfunction.
- Research-grade peptide bought online has not been verified for sterility, potency, or safety in humans.
Anyone considering bremelanotide for a medical condition should talk with a healthcare professional about prescription options rather than self-sourcing a research chemical.
Frequently Asked Questions
What is Alpha Peptides PT-141?
Alpha Peptides PT-141 is the research-grade bremelanotide peptide sold by the vendor Alpha Peptides. Bremelanotide is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder, but the research version is labeled for laboratory use only and is not approved for human consumption.
How long does PT-141 last?
After a subcutaneous injection, bremelanotide reaches peak blood levels in about an hour and has an elimination half-life of roughly 2.7 hours. Most users describe effects lasting several hours, commonly cited as six to twelve hours. The FDA label limits dosing to one injection every 24 hours.
Do you need a prescription to get PT-141?
Yes, if you want the FDA-approved drug, because bremelanotide is available by prescription as Vyleesi. Research-grade PT-141 sold online does not require a prescription, but it is sold strictly for laboratory use and has not been verified for human safety. A healthcare professional can advise on approved options.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.